Capricor Therapeutics Inc (NASDAQ: CAPR) is 206.95% higher on its value in year-to-date trading and has touched a low of $2.68 and a high of $15.65 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The CAPR stock was last observed hovering at around $15.21 in the last trading session, with the day’s loss setting it -0.2%.
Currently trading at $15.01, the stock is 142.72% and 199.35% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 12.82 million and changing -1.31% at the moment leaves the stock 195.19% off its SMA200. CAPR registered 338.89% gain for a year compared to 6-month loss of 117.85%. The firm has a 50-day simple moving average (SMA 50) of $5.2186 and a 200-day simple moving average (SMA200) of $5.13935.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a 228.45% gain in the last 1 month and extending the period to 3 months gives it a 218.01%, and is 64.95% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 29.71% over the week and 13.60% over the month.
Capricor Therapeutics Inc (CAPR) has around 102 employees, a market worth around $488.43M and $27.15M in sales. Profit margin for the company is -102.93%. Distance from 52-week low is 460.07% and -4.09% from its 52-week high. The company has generated returns on investments over the last 12 months (-175.51%).
with sales reaching $3.58M over the same period.The EPS is expected to shrink by -47.71% this year, but quarterly earnings will post -35.60% year-over-year. Quarterly sales are estimated to shrink -42.10% in year-over-year returns.
Capricor Therapeutics Inc (CAPR) Top Institutional Holders
86.0 institutions hold shares in Capricor Therapeutics Inc (CAPR), with institutional investors hold 37.17% of the company’s shares. The shares outstanding are 31.15M, and float is at 27.08M with Short Float at 27.79%. Institutions hold 28.48% of the Float.
The top institutional shareholder in the company is BLACKROCK INC. with over 1.63 million shares valued at $7.77 million. The investor’s holdings represent 5.194% of the CAPR Shares outstanding. As of 2024-06-30, the second largest holder is VANGUARD GROUP INC with 1.55 million shares valued at $7.39 million to account for 4.9401 of the shares outstanding. The other top investors are GEODE CAPITAL MANAGEMENT, LLC which holds 0.64 million shares representing 2.0462% and valued at over $3.06 million, while MILLENNIUM MANAGEMENT LLC holds 1.5293 of the shares totaling 0.48 million with a market value of $2.29 million.
Capricor Therapeutics Inc (CAPR) Insider Activity
The most recent transaction is an insider purchase by Nippon Shinyaku Co Ltd, the company’s 10% Owner. SEC filings show that Nippon Shinyaku Co Ltd bought 2,798,507 shares of the company’s common stock on Sep 20 ’24 at a price of $5.36 per share for a total of $15.0 million. Following the purchase, the insider now owns 7.09 million shares.
Capricor Therapeutics Inc disclosed in a document filed with the SEC on Oct 12 ’23 that Musket David B (Director) bought a total of 410 shares of the company’s common stock. The trade occurred on Oct 12 ’23 and was made at $2.75 per share for $1128.0. Following the transaction, the insider now directly holds 31536.0 shares of the CAPR stock.
Still, SEC filings show that on Oct 10 ’23, COLLIER EARL M JR (Director) acquired 10,000 shares at an average price of $2.83 for $28300.0. The insider now directly holds 26,856 shares of Capricor Therapeutics Inc (CAPR).
